Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 114 participants.
Also called NCT06701825
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 114 participants
- Registry
-
NCT06701825 -
2024-516596-32-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT06701825. Randomized; single masking; primary purpose treatment. Start 2025-06-02 (actual); primary completion 2026-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
- Acronym
- TRANSPGx
- Condition
- Kidney Disease, Chronic
- Condition
- Transplant Recipient (Kidney)
- Condition
- Immunosuppression
- Intervention (Drug)
- Tacrolimus
- Intervention (Drug)
- Tacrolimus
- Lead sponsor
- Instituto de Investigación Hospital Universitario La Paz
- Collaborator
- Instituto de Salud Carlos III
Record details
- Record id
cardio:ct-nct06701825- Content hash
c49cfa8ff5072bbda8696fc175d16e9530e65ff21fb286d9adcabd54fc65329b